Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.31 |
| ▸ | IL1B | P01584 | 4/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14998360 | 1.00 | KCNH2 (0.47) | KCNH2NPY5RSLC6A9ROCK2IL1B | |
| SCHEMBL14998358 | 0.90 | KCNH2 (0.41) | KCNH2NPY5RSLC6A9IL1BMAPT | |
| SCHEMBL2575025 | 0.90 | KCNH2 (0.45) | KCNH2NPY5RIL1B | |
| SCHEMBL12287721 | 0.90 | KCNH2 (0.58) | KCNH2NPY5RSLC6A9IL1BMAPT | |
| SCHEMBL17690324 | 0.89 | KCNH2 (0.45) | KCNH2MAPTHTT | |
| SCHEMBL16524629 | 0.88 | KCNH2 (0.36) | KCNH2NPY5RSLC6A9IL1B | |
| SCHEMBL14998315 | 0.88 | KCNH2 (0.47) | KCNH2SLC6A9ROCK2IL1BMAPT | |
| SCHEMBL2562548 | 0.88 | KCNH2 (0.47) | KCNH2SLC6A9ROCK2IL1BMAPT | |
| SCHEMBL14998239 | 0.87 | KCNH2 (0.49) | KCNH2NPY5RSLC6A9IL1BMAPT | |
| SCHEMBL14734703 | 0.87 | KCNH2 (0.47) | KCNH2NPY5RSLC6A9ROCK2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2563365-B1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE | CYTOKINETICS INC (US) | 2016-04-20 | — | — | EP | claimed |
| US-8969346-B2 | Amino-pyridazine skeletal muscle modulators | CYTOKINETICS, INC. (US) | 2015-03-03 | — | — | US | claimed |
| EP-3127541-B1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE | CYTOKINETICS INC (US) | 2019-07-17 | — | — | EP | disclosed |
| US-10076519-B2 | Substituted pyridazines as skeletal muscle modulators | CYTOKINETICS, INC. (US) | 2018-09-18 | — | — | US | disclosed |
| US-20170281621-A1 | SUBSTITUTED PYRIDAZINES AS SKELETAL MUSCLE MODULATORS | CYTOKINETICS INC (US) | 2017-10-05 | — | — | US | disclosed |
| US-9604965-B2 | Substituted pyridazines as skeletal muscle modulators | CYTOKINETICS, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| EP-3127541-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE | Cytokinetics, Inc. (US) | 2017-02-08 | — | — | EP | disclosed |
| EP-2563365-B1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE | CYTOKINETICS INC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-20150322018-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | ASHCRAFT LUKE W (US) | 2015-11-12 | — | — | US | disclosed |
| US-8969346-B2 | Amino-pyridazine skeletal muscle modulators | CYTOKINETICS, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20130143862-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE | CYTOKINETICS, INC. | 2013-06-06 | — | — | US | disclosed |
| EP-2563365-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE | Cytokinetics, Inc. (US) | 2013-03-06 | — | — | EP | disclosed |
| WO-2011133882-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE | CYTOKINETICS, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281621-A1 | SUBSTITUTED PYRIDAZINES AS SKELETAL MUSCLE MODULATORS | MUSK, PYGM, GYS1 | KCNH2 767/4885NPY5R 37/4885SLC6A9 521/4885 |
| US-10076519-B2 | Substituted pyridazines as skeletal muscle modulators | MUSK, PYGM, GYS1 | KCNH2 767/4885NPY5R 37/4885SLC6A9 521/4885 |
| US-20130143862-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE | SLC7A1, F12, C5 | KCNH2 442/4885NPY5R 13/4885SLC6A9 59/4885 |
| US-20150322018-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | SLC7A1, F12, C5 | KCNH2 441/4885NPY5R 11/4885SLC6A9 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.